Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Selection of Reference Regions to Model Neurodegeneration in Huntington Disease by 18F-FDG PET/CT Using Imaging and Clinical Parameters.

López Mora DA, Sampedro F, Camacho V, Fernández A, Fuentes F, Duch J, Pérez-Perez J, Martínez-Horta S, Marín-Lahoz J, Domènech A, Flotats A, Estorch M, Kulisevsky J, Carrió I.

Clin Nucl Med. 2018 Oct 15. doi: 10.1097/RLU.0000000000002329. [Epub ahead of print]

PMID:
30325816
2.

Parkinson's Disease: Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity.

Marín-Lahoz J, Pagonabarraga J, Martinez-Horta S, Fernandez de Bobadilla R, Pascual-Sedano B, Pérez-Pérez J, Gironell A, Kulisevsky J.

Front Psychiatry. 2018 Sep 28;9:465. doi: 10.3389/fpsyt.2018.00465. eCollection 2018.

PMID:
30323775
3.

Safinamide modulates striatal glutamatergic signalling in a rat model of levodopa-induced dyskinesia.

Gardoni F, Morari M, Kulisevsky J, Brugnoli A, Novello S, Pisano CA, Caccia C, Mellone M, Melloni E, Padoani G, Sosti V, Vailati S, Keywood C.

J Pharmacol Exp Ther. 2018 Oct 5. pii: jpet.118.251645. doi: 10.1124/jpet.118.251645. [Epub ahead of print]

4.

The impact of bilingualism on brain structure and function in Huntington's disease.

Martínez-Horta S, Moreu A, Perez-Perez J, Sampedro F, Horta-Barba A, Pagonabarraga J, Gomez-Anson B, Lozano-Martinez GA, Lopez-Mora DA, Camacho V, Fernández-León A, Carrió I, Kulisevsky J.

Parkinsonism Relat Disord. 2018 Sep 17. pii: S1353-8020(18)30405-X. doi: 10.1016/j.parkreldis.2018.09.017. [Epub ahead of print]

PMID:
30249427
5.

Angiotensin Type 1 Receptor Antagonists Protect Against Alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neuron Death.

Rodriguez-Perez AI, Sucunza D, Pedrosa MA, Garrido-Gil P, Kulisevsky J, Lanciego JL, Labandeira-Garcia JL.

Neurotherapeutics. 2018 Jul 9. doi: 10.1007/s13311-018-0646-z. [Epub ahead of print]

PMID:
29987762
6.

Validation of a simple screening tool for early diagnosis of advanced Parkinson's disease in daily practice: the CDEPA questionnaire.

Martinez-Martin P, Kulisevsky J, Mir P, Tolosa E, García-Delgado P, Luquin MR.

NPJ Parkinsons Dis. 2018 Jul 2;4:20. doi: 10.1038/s41531-018-0056-2. eCollection 2018.

7.

Early Gray Matter Volume Loss in MAPT H1H1 de Novo PD Patients: A Possible Association With Cognitive Decline.

Sampedro F, Marín-Lahoz J, Martínez-Horta S, Pagonabarraga J, Kulisevsky J.

Front Neurol. 2018 May 30;9:394. doi: 10.3389/fneur.2018.00394. eCollection 2018.

8.

Circadian Rhythm, Cognition, and Mood Disorders in Huntington's Disease.

Diago EB, Martínez-Horta S, Lasaosa SS, Alebesque AV, Pérez-Pérez J, Kulisevsky J, Del Val JL.

J Huntingtons Dis. 2018;7(2):193-198. doi: 10.3233/JHD-180291.

PMID:
29843249
9.

Update in therapeutic strategies for Parkinson's disease.

Kulisevsky J, Oliveira L, Fox SH.

Curr Opin Neurol. 2018 Aug;31(4):439-447. doi: 10.1097/WCO.0000000000000579.

PMID:
29746402
10.

Structural and metabolic brain correlates of apathy in Huntington's disease.

Martínez-Horta S, Perez-Perez J, Sampedro F, Pagonabarraga J, Horta-Barba A, Carceller-Sindreu M, Gomez-Anson B, Lozano-Martinez GA, Lopez-Mora DA, Camacho V, Fernández-León A, Carrió I, Kulisevsky J.

Mov Disord. 2018 Jul;33(7):1151-1159. doi: 10.1002/mds.27395. Epub 2018 Apr 20.

PMID:
29676484
11.

Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.

Cattaneo C, Kulisevsky J, Tubazio V, Castellani P.

Adv Ther. 2018 Apr;35(4):515-522. doi: 10.1007/s12325-018-0687-z. Epub 2018 Mar 14.

12.

Neurocardiovascular pathology in pre-manifest and early-stage Huntington's disease.

Bellosta Diago E, Pérez-Pérez J, Santos Lasaosa S, Viloria Alebesque A, Martínez-Horta S, Kulisevsky J, López Del Val J.

Eur J Neurol. 2018 Jul;25(7):956-962. doi: 10.1111/ene.13630. Epub 2018 Apr 16.

PMID:
29537687
13.

Historical crossroads in the conceptual delineation of apathy in Parkinson's disease.

Prange S, Pagonabarraga J, Krack P, Kulisevsky J, Sgambato V, Tremblay L, Thobois S, Broussolle E.

Brain. 2018 Feb 1;141(2):613-619. doi: 10.1093/brain/awx362. No abstract available.

PMID:
29329378
14.

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?

Catalán MJ, Antonini A, Calopa M, Băjenaru O, de Fábregues O, Mínguez-Castellanos A, Odin P, García-Moreno JM, Pedersen SW, Pirtošek Z, Kulisevsky J.

eNeurologicalSci. 2017 Jul 2;8:44-53. doi: 10.1016/j.ensci.2017.06.004. eCollection 2017 Sep. Review.

15.

[Safinamide from daily clinical practice: first clinical steps].

Pagonabarraga J, Kulisevsky J.

Rev Neurol. 2017 Nov 16;65(10):433-438. Spanish.

16.

Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients.

Garcia-Gorro C, de Diego-Balaguer R, Martínez-Horta S, Pérez-Pérez J, Kulisevsky J, Rodríguez-Dechicha N, Vaquer I, Subira S, Calopa M, Muñoz E, Santacruz P, Ruiz-Idiago J, Mareca C, Caballol N, Camara E.

Hum Brain Mapp. 2018 Jan;39(1):54-71. doi: 10.1002/hbm.23813. Epub 2017 Oct 8.

PMID:
28990240
17.

Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease.

Bellosta Diago E, Pérez Pérez J, Santos Lasaosa S, Viloria Alebesque A, Martínez Horta S, Kulisevsky J, López Del Val J.

Parkinsonism Relat Disord. 2017 Nov;44:95-100. doi: 10.1016/j.parkreldis.2017.09.013. Epub 2017 Sep 15.

PMID:
28935191
18.

Rotigotine transdermal patch and sleep in Parkinson's disease: where are we now?

Rosa-Grilo M, Qamar MA, Taddei RN, Pagonabarraga J, Kulisevsky J, Sauerbier A, Chaudhuri KR.

NPJ Parkinsons Dis. 2017 Sep 5;3:28. doi: 10.1038/s41531-017-0030-4. eCollection 2017. Review.

19.

Apathy in Parkinson's Disease.

Pagonabarraga J, Kulisevsky J.

Int Rev Neurobiol. 2017;133:657-678. doi: 10.1016/bs.irn.2017.05.025. Epub 2017 Jul 10. Review.

PMID:
28802937
20.

N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease.

García-Sanz P, Orgaz L, Bueno-Gil G, Espadas I, Rodríguez-Traver E, Kulisevsky J, Gutierrez A, Dávila JC, González-Polo RA, Fuentes JM, Mir P, Vicario C, Moratalla R.

Mov Disord. 2017 Oct;32(10):1409-1422. doi: 10.1002/mds.27119. Epub 2017 Aug 5.

PMID:
28779532
21.

Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS).

Fernández-Bobadilla R, Martínez-Horta S, Marín-Lahoz J, Horta-Barba A, Pagonabarraga J, Kulisevsky J.

Parkinsonism Relat Disord. 2017 Oct;43:73-77. doi: 10.1016/j.parkreldis.2017.07.015. Epub 2017 Jul 19.

PMID:
28754233
22.

Regional Overlap of Pathologies in Lewy Body Disorders.

Colom-Cadena M, Grau-Rivera O, Planellas L, Cerquera C, Morenas E, Helgueta S, Muñoz L, Kulisevsky J, Martí MJ, Tolosa E, Clarimon J, Lleó A, Gelpi E.

J Neuropathol Exp Neurol. 2017 Mar 1;76(3):216-224. doi: 10.1093/jnen/nlx002.

PMID:
28395086
23.

Consensus on the Definition of Advanced Parkinson's Disease: A Neurologists-Based Delphi Study (CEPA Study).

Luquin MR, Kulisevsky J, Martinez-Martin P, Mir P, Tolosa ES.

Parkinsons Dis. 2017;2017:4047392. doi: 10.1155/2017/4047392. Epub 2017 Jan 23.

24.

Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients.

Spataro N, Roca-Umbert A, Cervera-Carles L, Vallès M, Anglada R, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Kulisevsky J, Casals F, Clarimón J, Bosch E.

Mov Disord. 2017 Jan;32(1):165-169. doi: 10.1002/mds.26845. Epub 2016 Nov 7.

25.

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R.

JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.

PMID:
27942720
26.

Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes.

Martinez-Horta S, Sampedro F, Pagonabarraga J, Fernandez-Bobadilla R, Marin-Lahoz J, Riba J, Kulisevsky J.

Brain Imaging Behav. 2017 Oct;11(5):1334-1342. doi: 10.1007/s11682-016-9607-5.

PMID:
27730477
27.

Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [Parkinsonism Relat. Disord. 25C (2016) 58-64].

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Oct;31:161. doi: 10.1016/j.parkreldis.2016.08.011. Epub 2016 Aug 25. No abstract available.

PMID:
27567724
28.

Striatal hypometabolism in premanifest and manifest Huntington's disease patients.

López-Mora DA, Camacho V, Pérez-Pérez J, Martínez-Horta S, Fernández A, Sampedro F, Montes A, Lozano-Martínez GA, Gómez-Anson B, Kulisevsky J, Carrió I.

Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2183-2189. Epub 2016 Jun 28.

PMID:
27349245
29.

Normative Data for the Spanish Version of the Addenbrooke's Cognitive Examination III.

Matías-Guiu JA, Fernández-Bobadilla R, Fernández-Oliveira A, Valles-Salgado M, Rognoni T, Cortés-Martínez A, Moreno-Ramos T, Kulisevsky J, Matías-Guiu J.

Dement Geriatr Cogn Disord. 2016;41(5-6):243-50. doi: 10.1159/000445799. Epub 2016 Jun 1.

PMID:
27240425
30.

Erratum to: COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.

Santos-García D, Mir P, Cubo E, Vela L, Rodríguez-Oroz MC, Martí MJ, Arbelo JM, Infante J, Kulisevsky J, Martínez-Martín P; COPPADIS Study Group.

BMC Neurol. 2016 Apr 6;16:44. doi: 10.1186/s12883-016-0567-6. No abstract available.

31.

COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.

Santos-García D, Mir P, Cubo E, Vela L, Rodríguez-Oroz MC, Martí MJ, Arbelo JM, Infante J, Kulisevsky J, Martínez-Martín P; COPPADIS Study Group.

BMC Neurol. 2016 Feb 25;16:26. doi: 10.1186/s12883-016-0548-9. Erratum in: BMC Neurol. 2016;16:44.

32.

Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease.

Martinez-Horta S, Perez-Perez J, van Duijn E, Fernandez-Bobadilla R, Carceller M, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Ruiz-Idiago J, Sampedro F, Landwehrmeyer GB; Spanish REGISTRY investigators of the European Huntington's Disease Network, Kulisevsky J.

Parkinsonism Relat Disord. 2016 Apr;25:58-64. doi: 10.1016/j.parkreldis.2016.02.008. Epub 2016 Feb 11. Erratum in: Parkinsonism Relat Disord. 2016 Oct;31:161.

PMID:
26898966
33.

Parkinson's Disease--Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment.

Ruzafa-Valiente E, Fernández-Bobadilla R, García-Sánchez C, Pagonabarraga J, Martínez-Horta S, Kulisevsky J.

J Neurol Sci. 2016 Feb 15;361:66-71. doi: 10.1016/j.jns.2015.12.018. Epub 2015 Dec 11.

PMID:
26810519
34.

Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases.

Cervera-Carles L, Pagonabarraga J, Pascual-Sedano B, Pastor P, Campolongo A, Fortea J, Blesa R, Alcolea D, Morenas-Rodríguez E, Sala I, Lleó A, Kulisevsky J, Clarimón J.

Am J Med Genet B Neuropsychiatr Genet. 2016 Mar;171B(2):175-80. doi: 10.1002/ajmg.b.32390. Epub 2015 Oct 9.

PMID:
26453547
35.

MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.

Pastor P, Moreno F, Clarimón J, Ruiz A, Combarros O, Calero M, López de Munain A, Bullido MJ, de Pancorbo MM, Carro E, Antonell A, Coto E, Ortega-Cubero S, Hernandez I, Tárraga L, Boada M, Lleó A, Dols-Icardo O, Kulisevsky J, Vázquez-Higuera JL, Infante J, Rábano A, Fernández-Blázquez MÁ, Valentí M, Indakoetxea B, Barandiarán M, Gorostidi A, Frank-García A, Sastre I, Lorenzo E, Pastor MA, Elcoroaristizabal X, Lennarz M, Maier W, Rámirez A, Serrano-Ríos M, Lee SE, Sánchez-Juan P; Dementia Genetic Spanish Consortium (DEGESCO).

J Alzheimers Dis. 2016;49(2):343-52. doi: 10.3233/JAD-150555.

PMID:
26444794
36.

Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase.

Pagonabarraga J, Martinez-Horta S, Fernández de Bobadilla R, Pérez J, Ribosa-Nogué R, Marín J, Pascual-Sedano B, García C, Gironell A, Kulisevsky J.

Mov Disord. 2016 Jan;31(1):45-52. doi: 10.1002/mds.26432. Epub 2015 Sep 26. Erratum in: Mov Disord. 2016 Mar;31(3):433.

PMID:
26408291
37.

Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor.

Hor H, Francescatto L, Bartesaghi L, Ortega-Cubero S, Kousi M, Lorenzo-Betancor O, Jiménez-Jiménez FJ, Gironell A, Clarimón J, Drechsel O, Agúndez JA, Kenzelmann Broz D, Chiquet-Ehrismann R, Lleó A, Coria F, García-Martin E, Alonso-Navarro H, Martí MJ, Kulisevsky J, Hor CN, Ossowski S, Chrast R, Katsanis N, Pastor P, Estivill X.

Hum Mol Genet. 2015 Oct 15;24(20):5677-86. doi: 10.1093/hmg/ddv281. Epub 2015 Jul 17.

38.

Long-term response to continuous duodenal infusion of levodopa/carbidopa gel in patients with advanced Parkinson disease: The Barcelona registry.

Buongiorno M, Antonelli F, Cámara A, Puente V, de Fabregues-Nebot O, Hernandez-Vara J, Calopa M, Pascual-Sedano B, Campolongo A, Valldeoriola F, Tolosa E, Kulisevsky J, Martí MJ.

Parkinsonism Relat Disord. 2015 Aug;21(8):871-6. doi: 10.1016/j.parkreldis.2015.05.014. Epub 2015 May 19.

PMID:
26003410
39.

Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.

Pérez-Pérez J, Pagonabarraga J, Martínez-Horta S, Fernández-Bobadilla R, Sierra S, Pascual-Sedano B, Gironell A, Kulisevsky J.

Drugs Aging. 2015 May;32(5):401-7. doi: 10.1007/s40266-015-0264-y.

PMID:
25941103
40.

Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment.

Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P.

Lancet Neurol. 2015 May;14(5):518-31. doi: 10.1016/S1474-4422(15)00019-8. Epub 2015 Apr 12. Review.

PMID:
25895932
41.

Apathy: who cares?

Krack P, Pagonabarraga J, Strafella AP, Kulisevsky J.

Lancet Neurol. 2015 May;14(5):465. doi: 10.1016/S1474-4422(15)00031-9. Epub 2015 Apr 12. No abstract available.

PMID:
25895927
42.

Telling true from false: cannabis users show increased susceptibility to false memories.

Riba J, Valle M, Sampedro F, Rodríguez-Pujadas A, Martínez-Horta S, Kulisevsky J, Rodríguez-Fornells A.

Mol Psychiatry. 2015 Jun;20(6):772-7. doi: 10.1038/mp.2015.36. Epub 2015 Mar 31.

43.

Alterations in cerebral white matter and neuropsychology in patients with cirrhosis and falls.

Gómez-Ansón B, Román E, Fernández de Bobadilla R, Pires-Encuentra P, Díaz-Manera J, Núñez F, Martinez-Horta S, Vives-Gilabert Y, Pagonabarraga J, Kulisevsky J, Cordoba J, Guarner C, Soriano G.

PLoS One. 2015 Mar 20;10(3):e0118930. doi: 10.1371/journal.pone.0118930. eCollection 2015.

44.

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study.

Pagonabarraga J, Piñol G, Cardozo A, Sanz P, Puente V, Otermín P, Legarda I, Delgado T, Serrano C, Balaguer E, Aguirregomozcorta M, Álvarez R, Kulisevsky JJ.

Parkinsons Dis. 2015;2015:131508. doi: 10.1155/2015/131508. Epub 2015 Feb 22.

45.

Rasagiline for the treatment of parkinsonism in Huntington's disease.

Pérez-Pérez J, Martínez-Horta S, Pagonabarraga J, Carceller M, Kulisevsky J.

Parkinsonism Relat Disord. 2015 Mar;21(3):340-2. doi: 10.1016/j.parkreldis.2015.01.002. Epub 2015 Jan 10. No abstract available.

PMID:
25601128
46.

Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease.

Spataro N, Calafell F, Cervera-Carles L, Casals F, Pagonabarraga J, Pascual-Sedano B, Campolongo A, Kulisevsky J, Lleó A, Navarro A, Clarimón J, Bosch E.

Hum Mol Genet. 2015 Apr 1;24(7):2023-34. doi: 10.1093/hmg/ddu616. Epub 2014 Dec 11.

PMID:
25504046
47.

Validation of the Spanish version of Addenbrooke's Cognitive Examination III for diagnosing dementia.

Matias-Guiu JA, Fernández de Bobadilla R, Escudero G, Pérez-Pérez J, Cortés A, Morenas-Rodríguez E, Valles-Salgado M, Moreno-Ramos T, Kulisevsky J, Matías-Guiu J.

Neurologia. 2015 Nov-Dec;30(9):545-51. doi: 10.1016/j.nrl.2014.05.004. Epub 2014 Jul 4. English, Spanish.

48.

Therapeutic development paths for cognitive impairment in Parkinson's disease: report of a regulatory roundtable.

Eberling J, Vincent L, Goldman JG, Weintraub D, Kulisevsky J, Marras C, Stebbins G, Kieburtz K.

J Parkinsons Dis. 2014;4(4):585-9. doi: 10.3233/JPD-140385. Review.

49.

Apathy in Parkinson's disease: neurophysiological evidence of impaired incentive processing.

Martínez-Horta S, Riba J, de Bobadilla RF, Pagonabarraga J, Pascual-Sedano B, Antonijoan RM, Romero S, Mañanas MÀ, García-Sanchez C, Kulisevsky J.

J Neurosci. 2014 Apr 23;34(17):5918-26. doi: 10.1523/JNEUROSCI.0251-14.2014.

50.

The tools of the trade: a state of the art "How to Assess Cognition" in the patient with Parkinson's disease.

Marras C, Tröster AI, Kulisevsky J, Stebbins GT.

Mov Disord. 2014 Apr 15;29(5):584-96. doi: 10.1002/mds.25874. Review.

PMID:
24757108

Supplemental Content

Loading ...
Support Center